Udai Kammula
Clinical trials sponsored by Udai Kammula, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immune cell therapy shows promise against rare eye cancer Results expected Jul 2027 (estimated)
-
Immune cells take on rare bile duct cancer in early trial
Disease control OngoingThis early-phase trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink advanced bile duct cancers. Four participants receive chemotherapy to prepare their immune system, then an infusion of their own TIL cells plus high-dose ald…
Phase 2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Immune cell therapy shows promise for tough cancers
Disease control OngoingThis phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…
Phase 2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Immune cell therapy shows promise against rare eye cancer
Disease control OngoingThis phase 2 trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink tumors in people with metastatic uveal melanoma, a rare and aggressive eye cancer. Participants receive chemotherapy to prepare their immune system, then an infu…
Phase 2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC